Takeda Ventures, Inc. focuses its investments on high-caliber, early-stage, preclinical therapeutic and platform-based companies globally that complement Takeda's pipeline in areas like Oncology, Rare Genetics & Hematology, Neuroscience, and Gastrointestinal and Inflammation. Its strategy is to create strategic growth opportunities for Takeda by building, managing, and investing in innovative life science companies and supporting therapeutic innovation.
Portfolio
4
Fund Size
—
Top Stage
Series A
Last 12 Mo
2
Team
Stage Distribution
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Accipiter Biosciences | Seed | $12.7M | Nov 2025 |
| Integra Therapeutics | Series A | $10.7M | Sep 2025 |
| BridGene Biosciences | Series A | $12M | May 2021 |
| Amwell | Series C | $194M | May 2020 |
Top Co-Investors
Lombard Odier Investment Managers1 shared
Flying Fish1 shared
Columbus Venture Partners1 shared
Cercano Management1 shared
Washington Research Foundation1 shared
Alexandria Venture Investments1 shared
Argonautic Ventures1 shared
Last updated: 3 March 2026